These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 31875861)
21. Circulating tumor cells in breast cancer. Banys M; Müller V; Melcher C; Aktas B; Kasimir-Bauer S; Hagenbeck C; Hartkopf A; Fehm T Clin Chim Acta; 2013 Aug; 423():39-45. PubMed ID: 23623805 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of the prognostic significance of disseminated tumor cells in the bone marrow of primary, non-metastatic breast cancer patients after a 7-year follow-up. Hoffmann O; Schroer-Zuendorf IA; Kasimir-Bauer S; Oberhoff C; Kimmig R; Heubner M Arch Gynecol Obstet; 2015 Nov; 292(5):1117-25. PubMed ID: 25986892 [TBL] [Abstract][Full Text] [Related]
23. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Wülfing P; Borchard J; Buerger H; Heidl S; Zänker KS; Kiesel L; Brandt B Clin Cancer Res; 2006 Mar; 12(6):1715-20. PubMed ID: 16551854 [TBL] [Abstract][Full Text] [Related]
24. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Wallwiener M; Hartkopf AD; Baccelli I; Riethdorf S; Schott S; Pantel K; Marmé F; Sohn C; Trumpp A; Rack B; Aktas B; Solomayer EF; Müller V; Janni W; Schneeweiss A; Fehm TN Breast Cancer Res Treat; 2013 Jan; 137(2):503-10. PubMed ID: 23271327 [TBL] [Abstract][Full Text] [Related]
25. Pro-metastatic and mesenchymal gene expression signatures characterize circulating tumor cells of neuroblastoma patients with bone marrow metastases and relapse. Loh AHP; Angelina C; Wong MK; Tan SH; Sukhatme SA; Yeo T; Lim SB; Lee YT; Soh SY; Leung W; Chang KTE; Chua YW; Alkaff SMF; Lim TKH; Lim CT; Chen ZX Front Oncol; 2022; 12():939460. PubMed ID: 36176417 [TBL] [Abstract][Full Text] [Related]
26. Circulating and disseminated tumor cells in the management of breast cancer. Ross JS; Slodkowska EA Am J Clin Pathol; 2009 Aug; 132(2):237-45. PubMed ID: 19605818 [TBL] [Abstract][Full Text] [Related]
27. Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor. Beije N; Onstenk W; Kraan J; Sieuwerts AM; Hamberg P; Dirix LY; Brouwer A; de Jongh FE; Jager A; Seynaeve CM; Van NM; Foekens JA; Martens JW; Sleijfer S Neoplasia; 2016 Nov; 18(11):647-653. PubMed ID: 27764697 [TBL] [Abstract][Full Text] [Related]
28. Circulating and disseminated tumor cells in ovarian cancer: a systematic review. Romero-Laorden N; Olmos D; Fehm T; Garcia-Donas J; Diaz-Padilla I Gynecol Oncol; 2014 Jun; 133(3):632-9. PubMed ID: 24657303 [TBL] [Abstract][Full Text] [Related]
29. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer. Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662 [TBL] [Abstract][Full Text] [Related]
30. Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients. Kallergi G; Agelaki S; Papadaki MA; Nasias D; Matikas A; Mavroudis D; Georgoulias V Breast Cancer Res; 2015 Aug; 17(1):113. PubMed ID: 26285572 [TBL] [Abstract][Full Text] [Related]
31. Simultaneous detection of circulating and disseminated tumor cells in primary breast cancer patients following neoadjuvant chemotherapy. Walter VP; Taran FA; Wallwiener M; Hahn M; Brucker SY; Hartkopf AD Arch Gynecol Obstet; 2018 Mar; 297(3):785-790. PubMed ID: 29380106 [TBL] [Abstract][Full Text] [Related]
32. Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake? Kasimir-Bauer S; Reiter K; Aktas B; Bittner AK; Weber S; Keller T; Kimmig R; Hoffmann O Sci Rep; 2016 May; 6():26355. PubMed ID: 27212060 [TBL] [Abstract][Full Text] [Related]
33. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer. Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129 [TBL] [Abstract][Full Text] [Related]
34. Circulating tumor cells in breast cancer--current status and perspectives. Banys-Paluchowski M; Krawczyk N; Meier-Stiegen F; Fehm T Crit Rev Oncol Hematol; 2016 Jan; 97():22-9. PubMed ID: 26563820 [TBL] [Abstract][Full Text] [Related]
35. Relationship Between Hematogenous Tumor Cell Dissemination and Cellular Immunity in DCIS Patients. Gruber IV; Hartkopf AD; Hahn M; Taran FA; Staebler A; Wallwiener D; Brucker SY; Hanke J; Fehm T Anticancer Res; 2016 May; 36(5):2345-51. PubMed ID: 27127142 [TBL] [Abstract][Full Text] [Related]
36. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Fehm T; Müller V; Aktas B; Janni W; Schneeweiss A; Stickeler E; Lattrich C; Löhberg CR; Solomayer E; Rack B; Riethdorf S; Klein C; Schindlbeck C; Brocker K; Kasimir-Bauer S; Wallwiener D; Pantel K Breast Cancer Res Treat; 2010 Nov; 124(2):403-12. PubMed ID: 20859679 [TBL] [Abstract][Full Text] [Related]
37. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients. Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M; BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970 [TBL] [Abstract][Full Text] [Related]
38. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Fehm T; Braun S; Muller V; Janni W; Gebauer G; Marth C; Schindlbeck C; Wallwiener D; Borgen E; Naume B; Pantel K; Solomayer E Cancer; 2006 Sep; 107(5):885-92. PubMed ID: 16874814 [TBL] [Abstract][Full Text] [Related]
39. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells. Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758 [TBL] [Abstract][Full Text] [Related]
40. EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients. Alix-Panabières C Recent Results Cancer Res; 2012; 195():69-76. PubMed ID: 22527495 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]